INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study

Página do item simplificado
dc.contributor.authorde Andrade, Gabriel Costa [UNIFESP]
dc.contributor.authorde Oliveira Dias, Joao Rafael [UNIFESP]
dc.contributor.authorMaia, Andre [UNIFESP]
dc.contributor.authorFarah, Michel Eid [UNIFESP]
dc.contributor.authorMeyer, Carsten H. [UNIFESP]
dc.contributor.authorRodrigues, Eduardo Buchele [UNIFESP]
dc.date.accessioned2019-07-22T15:46:50Z
dc.date.available2019-07-22T15:46:50Z
dc.date.issued2016
dc.description.abstractPurpose:Diabetic macular edema is the leading cause of blindness in young adults in developed countries. Beyond metabolic control, several therapies have been studied such as laser treatment and intravitreal injections of corticosteroids or anti-vascular endothelial growth factor drugs. In terms of public health the long-term treatment with the current available drugs is very expensive and new therapies with the same or better effect should be investigated. This study sought to evaluate the efficacy and safety of intravitreal injections of ziv-aflibercept for the treatment of diabetic macular edema.Methods:Seven consecutive patients with diabetic macular edema were enrolled. A complete examination, including full-field electroretinography, visual acuity, central retinal thickness, and evaluation of systemic and ocular complications, was performed before and at 24 weeks after intravitreal injections of ziv-aflibercept. The seven patients were submitted to six consecutive intravitreal injections of ziv-aflibercept with a 4-week interval.Results:No significant differences were found in the amplitude or implicit time of any electroretinography component after intravitreal injections of ziv-aflibercept, and no systemic or ocular complication was observed. The improvement of visual acuity was significant at 24 weeks (P < 0.05). The central retinal thickness significantly decreased during the course of 24 weeks.Conclusion:Intravitreal injections of ziv-aflibercept seem to be a safe and effective treatment option for diabetic macular edema.en
dc.description.affiliationUniv Fed Sao Paulo, Dept Ophthalmol, Paulista Med Sch, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Ophthalmol, Paulista Med Sch, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP
dc.description.sponsorshipSao Paulo, Brazil)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq
dc.description.sponsorshipBrasilia, Brazil)
dc.description.sponsorshipPan-American Association of Ophthalmology/Pan-American Ophthamological Fundation, Paul Kayser Global Award (PAAO/PAOF
dc.description.sponsorshipArlington, Texas)
dc.format.extent1640-1645
dc.identifierhttp://dx.doi.org/10.1097/IAE.0000000000001000
dc.identifier.citationRetina-The Journal Of Retinal And Vitreous Diseases. Philadelphia, v. 36, n. 9, p. 1640-1645, 2016.
dc.identifier.doi10.1097/IAE.0000000000001000
dc.identifier.issn0275-004X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/51109
dc.identifier.wosWOS:000383979500006
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectdiabetic retinopathyen
dc.subjectdiabetic macular edema (DME)en
dc.subjectanti-VEGFen
dc.subjectziv-aflibercepten
dc.titleINTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Studyen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos